Decorin alleviates non-alcoholic fatty liver disease in rats with polycystic ovary syndrome

Endocrine multisystem defect polycystic ovary syndrome (PCOS) causes hyperandrogenism and infertility. Half
of PCOS women have (non-alcoholic fatty liver disease) NAFLD, which increases metabolic disease risk. We
tested decorin’s effect on NAFLD and related processes in PCOS. NAFLD+PCOS, PCOS+decorin, and control rats
were studied. Decorin was evaluated on NAFLD/PCOS rats. Test group rats received HF for eight weeks to
generate NAFLD. The rats got 1 mg/kg letrozole orally daily for 21 days to diagnosis PCOS. Afterward, rats got
injectable decorin for 14 days. Body weight, liver weight, liver coefficient Abdominal Circumference (AC) and
body mass index (BMI) were determined. Blood triglycerides (TG), total cholesterol, LDL-c, AST, and glucose
were measured. The insulin, testosterone, estrogen, LH, and FSH were measured by ELISA. GPx, SOD, MDA, TNF-
, and Caspase-3 liver immunohistochemistry were evaluated. NAFLD liver tissues in PCOS models showed
biochemical and histological alterations. NAFLD+PCOS raised BMI, AC, liver weight, and coefficient. Blood
glucose, insulin resistance, TG, ALT, and AST increased. Lipid abnormalities (TG, cholesterol, LDL-c, and HDL-c),
oxidative stress markers (MDA, SOD, and GPx), and liver dysfunction were found. Low serum E2 and high T
supported PCO. Decorin reduced model rat BMI, liver weight, coefficient, insulin resistance, TG, ALT, and AST. It
reduced liver inflammation, improved liver extract lipids, and normalized MDA, SOD, and GPx. In the model group, decorin lowered serum T, E2, LH, caspase 3, and TNF-alpha. Decorating improved NAFLD/PCOS group
liver histology and function. Decorin reduces hepatosteatosis by reducing liver inflammation, oxidative stress,
and dyslipidemia.